Resources & Insights

Three team members in our statistical programming internship role share their experience. In addition to working at PharPoint, all three are pursuing advanced degrees.

Investing in the Future of the Industry: PharPoint offers students who are just as passionate about improving global health as we are the experience and mentorship needed to thrive in the clinical research industry.

As the FDA continues to develop evolving guidelines, our industry has experienced a sudden, paradigm shift towards hybrid and virtual trials, with telemedicine becoming the “norm” for patient interaction across a variety of therapeutic areas.

As the situation with COVID-19 evolves, the PharPoint Research team is taking necessary precautions to ensure study operations continue uninterrupted. During this critical time in our industry, PharPoint remains fully dedicated, as always, to helping clients improve global health.

This February 29th, PharPoint acknowledges Rare Disease Day. We are relentless in supporting clients so that they may advance rare disease research and the approval of breakthrough treatments.

Information regarding the novel coronavirus is rapidly evolving as scientists and public-health officials race to uncover important details on the spread and treatment of the virus. Explore PharPoint’s news roundup and learn more about our extensive infectious disease experience.

How do you perform non-eCRF data (ECG, Labs, PK) reconciliation in EDC platforms like Medrio? A PharPoint clinical trial expert answers as part of our #askaclinicaltrialexpert blog series.

For our upcoming study, we know we want to use EDC—but there are so many options. How should we choose an EDC provider? As part of our Ask a Clinical Trial Expert blog series, a PharPoint clinical trial expert answers.

We’re worried that the service providers working on our study are causing it to fall behind. Timelines are being missed due to slow enrollment and data quality is poor. What are our options? A member of the PharPoint leadership team discusses options for study rescues in this Ask a Clinical Trial Expert blog series post.

What challenges exist between CROs and Sponsors—and is collaborative technology the answer, or something else?